Alk-Negative Anaplastic Large Cell Lymphoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ALK016 MIFTS: 49	Alk-Negative Anaplastic Large Cell Lymphoma Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Alk-Negative Anaplastic Large Cell Lymphoma

MalaCards integrated aliases for Alk-Negative Anaplastic Large Cell Lymphoma:

Name: Alk-Negative Anaplastic Large Cell Lymphoma ⁵⁹

Anaplastic Large Cell Lymphoma, Alk Negative ⁷³

Anaplastic Large Cell Lymphoma, Alk-Positive ⁷³

Alk- Anaplastic Large Cell Lymphoma ⁵⁹

Alk- Alcl ⁵⁹

Characteristics:

Orphanet epidemiological data:

⁵⁹

alk-negative anaplastic large cell lymphoma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Blood diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³⁴ ³³

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Mature T/NK-cell lymphomas

Anaplastic large cell lymphoma, ALK-negative

Orphanet: ⁵⁹

Rare haematological diseases

External Ids:

Orphanet ⁵⁹ ORPHA300903

UMLS via Orphanet ⁷⁴ C1332078

ICD10 via Orphanet ³⁴ C84.7

ICD10 ³³ C84.7

UMLS ⁷³ C1332078 C1332079

Sources

Summaries for Alk-Negative Anaplastic Large Cell Lymphoma

MalaCards based summary : Alk-Negative Anaplastic Large Cell Lymphoma, also known as anaplastic large cell lymphoma, alk negative, is related to alk-positive anaplastic large cell lymphoma and lymphoma. An important gene associated with Alk-Negative Anaplastic Large Cell Lymphoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Cyclophosphamide and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and breast, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Sources

Related Diseases for Alk-Negative Anaplastic Large Cell Lymphoma

Diseases in the Alk-Positive Anaplastic Large Cell Lymphoma family:

Alk-Negative Anaplastic Large Cell Lymphoma

Diseases related to Alk-Negative Anaplastic Large Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 53)

#	Related Disease	Score	Top Affiliating Genes
1	alk-positive anaplastic large cell lymphoma	32.7	ALK STAT3
2	lymphoma	31.5	ALK BAX BCL2 MYC
3	peripheral t-cell lymphoma	30.6	ALK CCR4 CXCR3
4	anaplastic large cell lymphoma	11.0
5	myelodysplastic syndrome	10.2
6	sarcoma	10.2
7	capillary leak syndrome	10.2
8	ichthyosis	10.2
9	hypereosinophilic syndrome	10.2
10	ichthyosis, acquired	10.2
11	lymphomatoid papulosis	10.2
12	soft tissue sarcoma	10.2
13	systemic capillary leak syndrome	10.2
14	high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement	10.2	BCL2 MYC
15	diffuse large b-cell lymphoma of the central nervous system	10.1	BCL2 MYC
16	differentiated thyroid carcinoma	10.1	ALK BCL2 CD274
17	kashin-beck disease	10.1	BAX BCL2
18	chronic venous leg ulcers	10.1	BCL2 MYC
19	lymphoma, hodgkin, classic	10.1
20	asthma	10.1
21	hematopoietic stem cell transplantation	10.1
22	pemphigus foliaceus	10.1
23	lymphocytic leukemia	10.1
24	syphilis	10.1
25	malignant teratoma	10.1	BAX BCL2
26	oral lichen planus	10.1	BAX CXCR3 TP63
27	primary mediastinal large b-cell lymphoma	10.1	BCL2 CD274 MYC
28	suppressor of tumorigenicity 3	10.1	BAX BCL2 MYC
29	myasthenic syndrome, congenital, 14	10.0	CD274 MYC
30	primary central nervous system lymphoma	10.0	BCL2 CD274
31	pleomorphic carcinoma	10.0	ALK CD274
32	hematologic cancer	10.0	ADA ALK BAX MYC
33	respiratory system cancer	9.9	ALK CD274 MYC STAT3
34	focal cortical dysplasia, type ii	9.9	BAX BCL2 BCL2L1
35	apical myocardial infarction	9.9	BCL2L1 STAT3
36	leukocyte disease	9.9	BAX BCL2L1 MYC
37	acute promyelocytic leukemia	9.8	BAX BCL2 MYC STAT3
38	follicular lymphoma	9.8	BCL2 BCL2L1 MYC
39	breast adenocarcinoma	9.8	BAX BCL2L1 MYC
40	mycosis fungoides	9.8	CCR4 CXCR3 DPP4 STAT3
41	b-cell lymphomas	9.7	BAX BCL2 BCL2L1 MYC
42	burkitt lymphoma	9.7	BAX BCL2 BCL2L1 MYC
43	cervical cancer	9.7	BAX BCL2 MYC STAT3 TP63
44	mantle cell lymphoma	9.7	BCL2 BCL2L1 MYC PMAIP1
45	lymphoma, non-hodgkin, familial	9.7	ALK BAX BCL2 BCL2L1 MYC
46	large intestine cancer	9.7	BCL2L1 CD274 MYC STAT3
47	lung cancer susceptibility 3	9.6	ALK BCL2L1 STAT3 TP63
48	squamous cell carcinoma, head and neck	9.6	BCL2L1 MYC STAT3 TP63
49	nasopharyngeal carcinoma	9.6	BCL2 BCL2L1 MYC STAT3
50	myeloma, multiple	9.6	BCL2L1 MYC PMAIP1 STAT3

Graphical network of the top 20 diseases related to Alk-Negative Anaplastic Large Cell Lymphoma:

Sources

Symptoms & Phenotypes for Alk-Negative Anaplastic Large Cell Lymphoma

GenomeRNAi Phenotypes related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-1	9.32	BAX BCL2 BCL2L1 DUSP22
2	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-2	9.32	BAX BCL2 BCL2L1 DUSP22 MYC TP63

MGI Mouse Phenotypes related to Alk-Negative Anaplastic Large Cell Lymphoma:

⁴⁶ (show all 14)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.2	ADA ALK BAX BCL2 BCL2L1 CD274
2	behavior/neurological	MP:0005386	10.19	ADARB1 ALK BAX BCL2 BCL2L1 CD274
3	growth/size/body region	MP:0005378	10.19	ADA ADARB1 ALK BAX BCL2 BCL2L1
4	cellular	MP:0005384	10.18	ADA BAX BCL2 BCL2L1 CD274 CXCR3
5	endocrine/exocrine gland	MP:0005379	10.16	ADA ALK BAX BCL2 BCL2L1 DPP4
6	hematopoietic system	MP:0005397	10.13	ADA BAX BCL2 BCL2L1 CCR4 CD274
7	immune system	MP:0005387	10.13	ADA BAX BCL2 BCL2L1 CCR4 CD274
8	mortality/aging	MP:0010768	10.11	ADA ADARB1 ALK BAX BCL2 BCL2L1
9	integument	MP:0010771	9.95	ALK BCL2 BCL2L1 CD274 MYC STAT3
10	muscle	MP:0005369	9.87	ADA ADARB1 BAX BCL2 MYC STAT3
11	neoplasm	MP:0002006	9.86	ALK BAX BCL2 BCL2L1 CXCR3 MYC
12	renal/urinary system	MP:0005367	9.63	ADA BAX BCL2 CXCR3 STAT3 TP63
13	reproductive system	MP:0005389	9.56	ADA ALK BAX BCL2 BCL2L1 MYC
14	respiratory system	MP:0005388	9.17	ADA ALK BAX CCR4 CXCR3 STAT3

Sources

Drugs & Therapeutics for Alk-Negative Anaplastic Large Cell Lymphoma

Drugs for Alk-Negative Anaplastic Large Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 44)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Cyclophosphamide

Approved, Investigational

Phase 4

6055-19-2, 50-18-0

2907

Gemcitabine

Approved

Phase 4

95058-81-4

60750

Vincristine

Approved, Investigational

Phase 4

57-22-7, 2068-78-2

5978

Etoposide

Approved

Phase 4

33419-42-0

36462

Dexamethasone

Approved, Investigational, Vet_approved

Phase 4

50-02-2

5743

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 4

1177-87-3

Cisplatin

Approved

Phase 4

15663-27-1

2767 441203 84093

Ifosfamide

Approved

Phase 4

3778-73-2

3690

Epirubicin

Approved

Phase 4

56420-45-2

41867

Prednisone

Approved, Vet_approved

Phase 4

53-03-2

5865

Mechlorethamine

Approved, Investigational

Phase 4

51-75-2

4033

Methotrexate

Approved

Phase 4

59-05-2, 1959-05-2

126941

leucovorin

Approved

Phase 4

58-05-9

6006 143

Doxorubicin

Approved, Investigational

Phase 4

23214-92-8

31703

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 4

59-30-3

6037

Doxil

Approved June 1999

Phase 4

31703

Pirarubicin

Investigational

Phase 4

72496-41-4

Isophosphamide mustard

Phase 4

Hormone Antagonists

Phase 4

Anti-Bacterial Agents

Phase 4

Antineoplastic Agents, Alkylating

Phase 4

Topoisomerase Inhibitors

Phase 4

Antibiotics, Antitubercular

Phase 4

Immunologic Factors

Phase 4

Antineoplastic Agents, Hormonal

Phase 4

Antimitotic Agents

Phase 4

Alkylating Agents

Phase 4

Hormones

Phase 4

Anti-Inflammatory Agents

Phase 4

Antineoplastic Agents, Phytogenic

Phase 4

Immunosuppressive Agents

Phase 4

BB 1101

Phase 4

Etoposide phosphate

Phase 4

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 4

Antirheumatic Agents

Phase 4

glucocorticoids

Phase 4

Folic Acid Antagonists

Phase 4

Dermatologic Agents

Phase 4

Vitamin B Complex

Phase 4

Antimetabolites

Phase 4

Folate

Phase 4

Antimetabolites, Antineoplastic

Phase 4

Vitamin B9

Phase 4

Nucleic Acid Synthesis Inhibitors

Phase 4

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL	Unknown status	NCT02533700	Phase 4	CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
2	CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma	Active, not recruiting	NCT01746992	Phase 4	Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
3	A Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK- Neoplasms	Recruiting	NCT03493451	Phase 2	BGB A317

Search NIH Clinical Center for Alk-Negative Anaplastic Large Cell Lymphoma

Sources

Genetic Tests for Alk-Negative Anaplastic Large Cell Lymphoma

Sources

Anatomical Context for Alk-Negative Anaplastic Large Cell Lymphoma

MalaCards organs/tissues related to Alk-Negative Anaplastic Large Cell Lymphoma:

⁴¹

T Cells, Bone, Breast, Bone Marrow, Lung, Thyroid, B Cells

Sources

Publications for Alk-Negative Anaplastic Large Cell Lymphoma

Articles related to Alk-Negative Anaplastic Large Cell Lymphoma:

(show top 50) (show all 55)

#	Title	Authors	Year
1	The Long Non-Coding RNA MIR503HG Enhances Proliferation of Human ALK-Negative Anaplastic Large-Cell Lymphoma. ( 29758012 )	Huang P.S....Lin K.H.	2018
2	Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. ( 29026208 )	Hu G....Feldman A.L.	2018
3	FOXP3-positive T-cell lymphomas in non-HTLV1 carriers include ALK-negative anaplastic large cell lymphoma: expanding the Spectrum of T-cell lymphomas with regulatory phenotype. ( 29898383 )		2018
4	Prognostic factors of ALK-negative anaplastic large-cell lymphoma: a single-institution experience. ( 29359238 )	Doghri R...Mrad K	2018
5	Acquired ichthyosis as a paraneoplastic feature of ALK-negative anaplastic large cell lymphoma. ( 30407628 )	Valchev G...Shivarov V	2018
6	ALK-Negative Anaplastic Large Cell Lymphoma Presenting as an Extranodal Soft-Tissue Mass With an Unusual Alveolar Growth Pattern: A Diagnostic Challenge. ( 28381153 )	AbdullGaffar B....Seliem R.M.	2017
7	DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. ( 28522440 )	Pedersen M.B....Feldman A.L.	2017
8	PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. ( 28344319 )	Atsaves V....Rassidakis G.Z.	2017
9	Indolent ALK-Negative Anaplastic Large Cell Lymphoma, DUSP22 Rearranged, with an Unusual Immunophenotype in an HIV Patient. ( 28042680 )	Chapman J....Vega F.	2017
10	Secondary CNS involvement of ALK-negative anaplastic large cell lymphoma. ( 28370436 )		2017
11	ALK-negative anaplastic large cell lymphoma with urinary bladder involvement diagnosed in urine cytology: A case report and literature review. ( 28139895 )	Lobo J...Lobo C	2017
12	The masquerading presentation of a systemic anaplastic large cell lymphoma, ALK positive: a case report and review of the literature. ( 28441913 )	Al-Ahmad S...Vandevenne M	2017
13	Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin. ( 26809026 )	Oregel K.Z....Nagaraj G.	2016
14	Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience. ( 27209536 )	Deng X.W....Li Y.X.	2016
15	ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin. ( 27460479 )		2016
16	ALK-negative anaplastic large cell lymphoma with loss of CD30 expression during treatment with brentuximab vedotin. ( 27263791 )		2016
17	Primary rare anaplastic large cell lymphoma, ALK positive in small intestine: case report and review of the literature. ( 27612448 )		2016
18	ALK-negative anaplastic large-cell lymphoma. ( 26769771 )		2016
19	ALK-negative anaplastic large cell lymphoma is sensitive to bortezomib through Noxa upregulation and release of Bax from Bcl-2. ( 25975837 )	Cillessen S.A....Meijer C.J.	2015
20	Primary pancreatic ALK negative anaplastic large cell lymphoma. ( 25474521 )	Mishra P....Sachdev R.	2015
21	A case of ALK negative anaplastic large cell lymphoma with leukaemic manifestation, transformed from CD4 positive T-cell large granular lymphocytic leukaemia. ( 25474523 )	Kim J....Suh C.	2015
22	Progress in the identification of subgroups in ALK-negative anaplastic large-cell lymphoma. ( 26223379 )	Boddicker R.L....Feldman A.L.	2015
23	Axillary Lymphadenopathy: An Outstanding Presentation for Breast Implant-Associated ALK-Negative Anaplastic Large Cell Lymphoma. ( 25829459 )		2015
24	PAX5-expressing ALK-negative anaplastic large cell lymphoma with extensive extranodal and nodal involvement. ( 26187868 )		2015
25	Flow cytometry of ALK-negative anaplastic large cell lymphoma of breast implant-associated effusion and capsular tissue. ( 24976005 )	Wu D....Fromm J.R.	2014
26	ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. ( 24894770 )	Parrilla Castellar E.R....Feldman A.L.	2014
27	Flow cytometry of ALK-negative anaplastic large cell lymphoma of breast implant-associated effusion and capsular tissue. ( 25044944 )		2014
28	Breast implant-associated ALK-negative anaplastic large cell lymphoma: a case report and discussion of possible pathogenesis. ( 23923082 )	George E.V....Yang L.J.	2013
29	Intravascular ALK-negative anaplastic large cell lymphoma with localized cutaneous involvement and an indolent clinical course: toward recognition of a distinct clinicopathologic entity. ( 23480896 )	Metcalf R.A....Gratzinger D.	2013
30	Composite ALK-negative anaplastic large cell lymphoma and small lymphocytic lymphoma involving the right inguinal lymph node. ( 24169448 )	Persad P....Pang C.S.	2013
31	Refractory Case of ALK-Negative Anaplastic Large-Cell Lymphoma with PAX-5 Expression and T-Cell Receptor-I^ Gene Rearrangement. ( 24369229 )	Kawakami K....Nakamura S.	2013
32	ALK-negative anaplastic large cell lymphoma primarily involving the bronchus: a case report and literature review. ( 24427373 )		2013
33	Lymphohistiocytic and small cell pattern of anaplastic large cell lymphoma, ALK positive, arising in an 86-year-old woman. ( 23692425 )		2013
34	Two cases of CD30+, anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma with oral manifestations. ( 22940020 )	Grandhi A...Freedman PD	2013
35	Systemic Capillary Leak Syndrome as an Initial Presentation of ALK-Negative Anaplastic Large Cell Lymphoma. ( 22953081 )	Lourdes L.S....Markham M.J.	2012
36	Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. ( 22740451 )	Agnelli L....Piva R.	2012
37	High-risk ALK negative anaplastic large-cell lymphoma presenting with hypereosinophilic syndrome in a 2.5-year-old child. ( 23013405 )	TekkeA9in F....AkyA1rek N.	2012
38	Anaplastic large cell lymphoma, ALK-positive. ( 22440390 )	Ferreri A.J....Savage K.J.	2012
39	Leukemic presentation of ALK-negative anaplastic large cell lymphoma in a patient with myelodysplastic syndrome. ( 22246491 )		2012
40	Pathobiology of ALK-negative anaplastic large cell lymphoma. ( 22053281 )	Pileri S.A....Piccaluga P.P.	2011
41	ALK-negative anaplastic large cell lymphoma mimicking a soft tissue sarcoma. ( 22090705 )	Hudacko R....Simsir A.	2011
42	Rapid fatal pulmonary complications in a Chinese patient after bortezomib treatment for ALK-negative anaplastic large-cell lymphoma. ( 20371451 )	Zhou X....Guo H.	2010
43	Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma. ( 20217288 )	Asano N....Nakamura S.	2010
44	Secondary ALK negative anaplastic large cell lymphoma in a patient with lymphomatoid papulosis of 40 years duration. ( 20644462 )	MarschalkA^ M....Csomor J.	2010
45	ALK-negative anaplastic large cell lymphoma with extensive peripheral blood and bone marrow involvements manifested as &quot;leukemic phase&quot;. ( 19695703 )		2010
46	ALK-negative anaplastic large cell lymphoma in leukemic phase with near-pentaploidy. ( 20846102 )		2010
47	A case of anaplastic large cell lymphoma, ALK positive, primary presented in the skin and relapsed with systemic involvement and leukocytosis after years of follow-up period. ( 20976631 )	Hosoi M...Kurokawa M	2010
48	Cutaneous presentation on the eyelid of primary, systemic, CD30+, anaplastic lymphoma kinase (ALK)-negative, anaplastic large-cell lymphoma (ALCL). ( 16796648 )		2006
49	CD26, together with cell surface adenosine deaminase, is selectively expressed on ALK-positive, but not on ALK-negative, anaplastic large cell lymphoma and Hodgkin's lymphoma. ( 17071493 )		2006
50	Primary pancreatic anaplastic large cell lymphoma, ALK negative: a case report. ( 16273656 )	Savopoulos CG...Kostopoulos IS	2005

Sources

Genes for Alk-Negative Anaplastic Large Cell Lymphoma

Genes related to Alk-Negative Anaplastic Large Cell Lymphoma (0 elite genes):

(show all 16)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	ALK	ALK Receptor Tyrosine Kinase	Protein Coding	18.63	GeneCards inferred via : Publications (show sections)
2	DUSP22	Dual Specificity Phosphatase 22	Protein Coding	17.93	GeneCards inferred via : Publications (show sections)
3	CD274	CD274 Molecule	Protein Coding	17.38	GeneCards inferred via : Publications (show sections)
4	ADA	Adenosine Deaminase	Protein Coding	17.38	GeneCards inferred via : Publications (show sections)
5	BAX	BCL2 Associated X, Apoptosis Regulator	Protein Coding	17.38	GeneCards inferred via : Publications (show sections)
6	ADARB1	Adenosine Deaminase, RNA Specific B1	Protein Coding	17.38	GeneCards inferred via : Publications (show sections)
7	CXCR3	C-X-C Motif Chemokine Receptor 3	Protein Coding	17.38	GeneCards inferred via : Publications (show sections)
8	DPP4	Dipeptidyl Peptidase 4	Protein Coding	17.38	GeneCards inferred via : Publications (show sections)
9	BCL2	BCL2, Apoptosis Regulator	Protein Coding	17.38	GeneCards inferred via : Publications (show sections)
10	TP63	Tumor Protein P63	Protein Coding	17.38	GeneCards inferred via : Publications (show sections)
11	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	17.38	GeneCards inferred via : Publications (show sections)
12	PMAIP1	Phorbol-12-Myristate-13-Acetate-Induced Protein 1	Protein Coding	17.38	GeneCards inferred via : Publications (show sections)
13	STAT3	Signal Transducer And Activator Of Transcription 3	Protein Coding	17.38	GeneCards inferred via : Publications (show sections)
14	CCR4	C-C Motif Chemokine Receptor 4	Protein Coding	7.38	GeneCards inferred via : Publications (show sections)
15	BCL2L1	BCL2 Like 1	Protein Coding	7.38	GeneCards inferred via : Publications (show sections)
16	MIR503HG	MIR503 Host Gene	RNA Gene	7.38	GeneCards inferred via : Publications (show sections)

Sources

Variations for Alk-Negative Anaplastic Large Cell Lymphoma

Sources

Expression for Alk-Negative Anaplastic Large Cell Lymphoma

Search GEO for disease gene expression data for Alk-Negative Anaplastic Large Cell Lymphoma.

Sources

Pathways for Alk-Negative Anaplastic Large Cell Lymphoma

Pathways related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show top 50) (show all 57)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.81	ALK BAX BCL2 BCL2L1 CCR4 CXCR3
2	PEDF Induced Signaling ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Cytokine-cytokine receptor interaction ³⁷ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Mediated Glucocorticoid Regulation ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.64	ALK BAX BCL2 BCL2L1 CCR4 CXCR3
3	Human cytomegalovirus infection ³⁷ Show member pathways Hepatitis B ³⁷ Human immunodeficiency virus 1 infection ³⁷ Kaposi sarcoma-associated herpesvirus infection ³⁷	13	BAX BCL2 BCL2L1 CCR4 MYC STAT3
4	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.78	BAX BCL2 BCL2L1 MYC PMAIP1 STAT3
5	Glioma ³⁷ Show member pathways EGFR tyrosine kinase inhibitor resistance ³⁷ Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.74	ALK BAX BCL2 BCL2L1 STAT3
6	Apoptosis Modulation and Signaling ¹ Show member pathways Apoptosis ¹ Apoptosis ³⁷ Apoptosis and survival Apoptotic TNF-family pathways ²² Apoptosis Signaling Pathways ⁶⁵ Death Receptor Signaling ⁶⁷	12.7	BAX BCL2 BCL2L1 MYC PMAIP1 TP63
7	4-1BB Pathway ⁶⁴ Show member pathways CD27 Pathway ⁶⁴ CD40 Signaling ⁶⁴ CMV and MAPK Pathways ⁶⁴ NF-KappaB Activation by EBV ⁶⁴ NF-kappaB Activation by Viruses ⁶⁴ PKR Pathway ⁶⁴ SUMO Pathway ⁶⁴ TNFR2 Pathway ⁶⁴	12.65	BAX BCL2 BCL2L1 PMAIP1 STAT3
8	Th17 cell differentiation ³⁷ Show member pathways IL-22 Pathway ⁶⁴ Immune response IL-22 signaling pathway ²² Inflammatory bowel disease (IBD) ³⁷ Th1 and Th2 cell differentiation ³⁷	12.55	BCL2 BCL2L1 MYC STAT3
9	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²² Rac1/Pak1/p38/MMP-2 pathway ¹	12.54	BAX BCL2 BCL2L1 MYC STAT3
10	Development Dopamine D2 receptor transactivation of EGFR ²² Show member pathways Apoptosis and survival BAD phosphorylation ²² BAD Phosphorylation ⁶⁴ Chemotaxis CXCR4 signaling pathway ²² Development Alpha-2 adrenergic receptor activation of ERK ²²	12.53	BAX BCL2 BCL2L1 STAT3
11	Pathways in cancer ³⁷	12.52	ALK BAX BCL2 BCL2L1 MYC PMAIP1
12	MicroRNAs in cancer ³⁷	12.48	BCL2 MYC STAT3 TP63
13	Prolactin Signaling Pathway ¹ ³⁷ Show member pathways Development Prolactin receptor signaling ²² Leptin signaling pathway ¹	12.4	BAX BCL2 BCL2L1 MYC STAT3
14	JAK-STAT signaling pathway (KEGG) ³⁷ Show member pathways Interleukin-19, 20, 22, 24 ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵	12.36	BCL2 BCL2L1 MYC STAT3
15	Development IGF-1 receptor signaling ²² Show member pathways IL-4 Signaling Pathway ¹ Immune response IL-4 signaling pathway ²² Signal transduction AKT signaling ²²	12.36	BAX BCL2L1 MYC STAT3
16	Epstein-Barr virus infection ³⁷	12.27	BAX BCL2 MYC STAT3
17	Viral carcinogenesis ³⁷	12.27	BAX CCR4 PMAIP1 STAT3
18	DNA Damage Response ¹ Show member pathways miRNA Regulation of DNA Damage Response ¹ p53 signaling pathway ³⁷	12.24	BAX BCL2 BCL2L1 MYC PMAIP1
19	MAPK Signaling: Mitogen Stimulation Pathway ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.17	BAX BCL2 BCL2L1 MYC
20	Colorectal Cancer Metastasis ⁶⁴	12.15	BAX BCL2L1 MYC STAT3
21	AKT Signaling Pathway ⁶⁷	12.11	BAX BCL2 BCL2L1 MYC
22	Immune response IFN gamma signaling pathway ²² Show member pathways IFN-gamma pathway ¹	12.03	BAX BCL2 MYC STAT3
23	Apoptosis and Autophagy ⁴	12.03	BAX BCL2 BCL2L1 MYC PMAIP1
24	IL-2 Signaling Pathway ¹ Show member pathways IL2-mediated signaling events ¹ IL-5 Signaling Pathway ¹	12.02	BCL2 MYC STAT3
25	Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers ⁶⁵	12.02	MYC STAT3 TP63
26	Direct p53 effectors ¹	12.02	BAX BCL2 PMAIP1 TP63
27	Amyotrophic lateral sclerosis (ALS) ¹ ³⁷ Show member pathways Pathogenesis of ALS ⁶⁴	11.94	BAX BCL2 BCL2L1
28	DNA Damage Response (only ATM dependent) ¹	11.94	BAX BCL2 MYC PMAIP1
29	Interleukin-4 and 13 signaling ⁶⁶	11.93	BCL2 BCL2L1 MYC STAT3
30	TP53 Regulates Transcription of Cell Death Genes ⁶⁶ Show member pathways The IPAF inflammasome ⁶⁶ TP53 Regulates Transcription of Caspase Activators and Caspases ⁶⁶ TP53 Regulates Transcription of Death Receptors and Ligands ⁶⁶ TP53 Regulates Transcription of Genes Involved in Cytochrome C Release ⁶⁶ TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain ⁶⁶	11.91	BAX PMAIP1 TP63
31	AGE-RAGE signaling pathway in diabetic complications ³⁷	11.87	BAX BCL2 STAT3
32	IL6-mediated signaling events ¹ Show member pathways IL-6 signaling pathway ¹	11.81	BCL2L1 MYC STAT3
33	Development EPO-induced Jak-STAT pathway ²² Show member pathways EPO Receptor Signaling ¹ EPO signaling pathway ¹	11.8	BCL2 BCL2L1 MYC STAT3
34	Validated targets of C-MYC transcriptional activation ¹	11.77	BAX MYC PMAIP1
35	Small cell lung cancer ³⁷	11.76	BAX BCL2 BCL2L1 MYC
36	C-MYB transcription factor network ¹	11.75	ADA BCL2 MYC
37	Nanomaterial induced apoptosis ¹ Show member pathways Activation and oligomerization of BAK protein ⁶⁶ Apoptosis - multiple species ³⁷ Apoptosis Modulation by HSP70 ¹ Apoptotic factor-mediated response ⁶⁶ Release of apoptotic factors from the mitochondria ⁶⁶	11.68	BAX BCL2 BCL2L1 PMAIP1
38	IL2 signaling events mediated by PI3K ¹ Show member pathways IL2 signaling events mediated by STAT5 ¹	11.67	BCL2 BCL2L1 MYC
39	Activation of BH3-only proteins ⁶⁶ Show member pathways Activation of BAD and translocation to mitochondria ⁶⁶ Activation of BIM and translocation to mitochondria ⁶⁶ Activation of BMF and translocation to mitochondria ⁶⁶ Activation of NOXA and translocation to mitochondria ⁶⁶ Activation of PUMA and translocation to mitochondria ⁶⁶ Activation, myristolyation of BID and translocation to mitochondria ⁶⁶ BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members ⁶⁶ Intrinsic Pathway for Apoptosis ⁶⁶	11.65	BAX BCL2 BCL2L1 PMAIP1 TP63
40	Platinum drug resistance ³⁷	11.6	BAX BCL2 BCL2L1 PMAIP1
41	Hepatitis C and Hepatocellular Carcinoma ¹	11.53	BCL2L1 MYC STAT3
42	Photodynamic therapy-induced AP-1 survival signaling. ¹	11.53	BAX BCL2 BCL2L1
43	IL-7 Signaling Pathway ¹ Show member pathways B-Cell Development ⁶⁴ IL-9 Signaling Pathway ¹	11.48	BCL2L1 MYC STAT3
44	Integrated Cancer Pathway ¹	11.47	BAX BCL2 MYC
45	Ceramide signaling pathway ¹	11.44	BAX BCL2 MYC
46	Photodynamic therapy-induced HIF-1 survival signaling ¹	11.36	BAX BCL2L1 PMAIP1
47	IL-10 Pathway ⁶⁴	11.33	BCL2L1 MYC STAT3
48	14-3-3 and Regulation of BAD Activity ⁶⁴	11.27	BAX BCL2 BCL2L1
49	Busulfan Pathway, Pharmacodynamics ⁶¹ Show member pathways Catalytic cycle of mammalian Flavin-containing MonoOxygenases (FMOs) ¹ FMO oxidises nucleophiles ⁶⁶	11.27	BCL2 BCL2L1 MYC STAT3
50	Apoptosis and survival_Regulation of Apoptosis by Mitochondrial Proteins ²² Show member pathways Vpr-mediated induction of apoptosis by mitochondrial outer membrane permeabilization ⁶⁶	11.26	BAX BCL2 BCL2L1 PMAIP1

Sources

GO Terms for Alk-Negative Anaplastic Large Cell Lymphoma

Cellular components related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	external side of plasma membrane	GO:0009897	9.56	ADA CCR4 CD274 CXCR3
2	pore complex	GO:0046930	9.16	BAX BCL2
3	Bcl-2 family protein complex	GO:0097136	8.96	BAX BCL2L1
4	mitochondrial outer membrane	GO:0005741	8.92	BAX BCL2 BCL2L1 PMAIP1

Biological processes related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 42)

#	Name	GO ID	Score	Top Affiliating Genes
1	response to drug	GO:0042493	9.95	ADA BCL2 MYC STAT3
2	cytokine-mediated signaling pathway	GO:0019221	9.94	BCL2 BCL2L1 MYC STAT3
3	regulation of cell cycle	GO:0051726	9.89	ADARB1 BAX BCL2 STAT3
4	negative regulation of neuron apoptotic process	GO:0043524	9.86	BAX BCL2 BCL2L1
5	negative regulation of cell migration	GO:0030336	9.85	ADARB1 BCL2 DUSP22
6	regulation of apoptotic process	GO:0042981	9.85	ALK BAX BCL2 BCL2L1 PMAIP1 TP63
7	cellular response to hypoxia	GO:0071456	9.84	BCL2 MYC PMAIP1
8	male gonad development	GO:0008584	9.83	BAX BCL2 BCL2L1
9	intrinsic apoptotic signaling pathway in response to DNA damage	GO:0008630	9.77	BAX BCL2 BCL2L1
10	response to radiation	GO:0009314	9.75	BCL2 BCL2L1 CCR4
11	extrinsic apoptotic signaling pathway in absence of ligand	GO:0097192	9.74	BAX BCL2 BCL2L1
12	response to cytokine	GO:0034097	9.73	BCL2 BCL2L1 CD274 STAT3
13	response to gamma radiation	GO:0010332	9.72	BAX BCL2 MYC
14	regulation of mitochondrial membrane potential	GO:0051881	9.71	BAX BCL2 BCL2L1
15	ovarian follicle development	GO:0001541	9.71	BAX BCL2 BCL2L1 MYC
16	negative regulation of intrinsic apoptotic signaling pathway	GO:2001243	9.69	BCL2 BCL2L1
17	B cell homeostasis	GO:0001782	9.68	BAX BCL2
18	homeostasis of number of cells	GO:0048872	9.68	BAX CCR4
19	mitochondrion morphogenesis	GO:0070584	9.68	BAX BCL2L1
20	positive regulation of smooth muscle cell migration	GO:0014911	9.67	BCL2 MYC
21	positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway	GO:1900740	9.67	BCL2 PMAIP1 TP63
22	positive regulation of protein oligomerization	GO:0032461	9.66	BAX PMAIP1
23	endoplasmic reticulum calcium ion homeostasis	GO:0032469	9.66	BAX BCL2
24	hypothalamus development	GO:0021854	9.65	BAX MYC
25	apoptotic mitochondrial changes	GO:0008637	9.65	BAX BCL2 BCL2L1
26	regulation of cysteine-type endopeptidase activity involved in apoptotic process	GO:0043281	9.64	BAX TP63
27	positive regulation of ATP biosynthetic process	GO:2001171	9.63	MYC STAT3
28	regulation of protein heterodimerization activity	GO:0043497	9.63	BAX BCL2
29	protein insertion into mitochondrial membrane involved in apoptotic signaling pathway	GO:0001844	9.62	BAX PMAIP1
30	neuron apoptotic process	GO:0051402	9.62	BAX BCL2 BCL2L1 TP63
31	regulation of protein homodimerization activity	GO:0043496	9.61	BAX BCL2
32	leukocyte homeostasis	GO:0001776	9.61	BAX BCL2
33	regulation of cell-cell adhesion mediated by integrin	GO:0033632	9.58	ADA DPP4
34	positive regulation of intrinsic apoptotic signaling pathway	GO:2001244	9.56	BAX BCL2 BCL2L1 PMAIP1
35	positive regulation of developmental pigmentation	GO:0048087	9.52	BAX BCL2
36	regulation of nitrogen utilization	GO:0006808	9.51	BAX BCL2
37	release of cytochrome c from mitochondria	GO:0001836	9.46	BAX BCL2 BCL2L1 PMAIP1
38	regulation of mitochondrial membrane permeability	GO:0046902	9.26	BCL2 BCL2L1 PMAIP1 STAT3
39	cell proliferation	GO:0008283	9.23	ALK BAX BCL2 BCL2L1 DUSP22 MYC
40	negative regulation of apoptotic process	GO:0043066	10.03	ADA ALK BCL2 BCL2L1 MYC STAT3
41	positive regulation of cell proliferation	GO:0008284	10.02	BCL2 BCL2L1 DPP4 MYC STAT3
42	apoptotic process	GO:0006915	10	BAX BCL2 BCL2L1 CXCR3 DUSP22 PMAIP1

Molecular functions related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	identical protein binding	GO:0042802	9.5	ALK BAX BCL2 BCL2L1 DPP4 STAT3
2	C-C chemokine binding	GO:0019957	9.37	CCR4 CXCR3
3	C-C chemokine receptor activity	GO:0016493	9.32	CCR4 CXCR3
4	chemokine receptor activity	GO:0004950	9.26	CCR4 CXCR3
5	adenosine deaminase activity	GO:0004000	9.16	ADA ADARB1
6	BH3 domain binding	GO:0051434	8.8	BAX BCL2 BCL2L1

Sources

Sources for Alk-Negative Anaplastic Large Cell Lymphoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia